Sarepta Therapeutics (SRPT) Financials

$23.12 -0.14 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$23.24 +0.12 (+0.50%)

As of 04:57 PM Eastern

Annual Income Statements for Sarepta Therapeutics

This table shows Sarepta Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-220	-267	-51	-362	-715	-554	-419	-703	-536	235
Consolidated Net Income / (Loss)	-220	-267	-51	-362	-715	-554	-419	-703	-536	235
Net Income / (Loss) Continuing Operations	-220	-267	-51	-362	-715	-554	-419	-703	-536	235
Total Pre-Tax Income	-220	-267	-49	-363	-714	-553	-419	-690	-520	261
Total Operating Income	-220	-267	-172	-344	-706	-564	-460	-536	-268	218
Total Gross Profit	1.25	5.42	155	301	381	540	702	933	1,243	1,902
Total Revenue	1.25	5.42	155	301	381	540	702	933	1,243	1,902
Operating Revenue	1.25	5.42	155	301	381	540	702	933	1,243	1,902
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	221	272	326	645	1,086	1,104	1,162	1,469	1,511	1,684
Selling, General & Admin Expense	75	84	123	208	285	318	283	451	482	558
Research & Development Expense	146	188	167	402	734	722	771	877	877	805
Amortization Expense	-	0.03	1.05	0.87	0.85	0.66	0.71	0.71	1.56	2.41
Other Operating Expenses / (Income)	-	0.10	36	34	67	63	107	140	150	319
Total Other Income / (Expense), net	0.15	-0.54	123	-19	-8.32	11	41	-154	-252	43
Interest Expense	-	-	-	-	-	0.00	0.00	125	387	0.00
Other Income / (Expense), net	0.15	-0.54	123	-19	-8.32	11	41	-28	135	43
Income Tax Expense	-	-	2.06	-0.69	1.20	1.06	-0.17	14	16	26
Basic Earnings per Share	($5.20)	($5.49)	($0.86)	($5.46)	($9.71)	($7.11)	($5.15)	($8.03)	($5.80)	$2.47
Weighted Average Basic Shares Outstanding	42.29M	48.70M	58.82M	66.25M	73.62M	77.96M	81.26M	87.56M	92.40M	95.08M
Diluted Earnings per Share	($5.20)	($5.49)	($0.86)	($5.46)	($9.71)	($7.11)	($5.15)	($8.03)	($5.80)	$2.34
Weighted Average Diluted Shares Outstanding	42.29M	48.70M	58.82M	66.25M	73.62M	77.96M	81.26M	87.56M	92.40M	107.88M
Weighted Average Basic & Diluted Shares Outstanding	42.29M	48.70M	58.82M	66.25M	73.62M	77.96M	81.26M	87.98M	93.86M	97.03M

This table shows Sarepta Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-258	-143	-517	-25	-41	46	36	6.12	37	156	-448
Consolidated Net Income / (Loss)	-258	-109	-517	-24	-41	46	36	6.46	34	159	-448
Net Income / (Loss) Continuing Operations	-258	-143	-517	-24	-41	46	36	6.46	34	159	-448
Total Pre-Tax Income	-256	-101	-513	-15	-33	40	41	14	34	172	-384
Total Operating Income	-131	-107	-138	-134	-21	25	35	-0.70	22	162	-300
Total Gross Profit	230	258	254	261	332	397	413	363	467	658	745
Total Revenue	230	258	254	261	332	397	413	363	467	658	745
Operating Revenue	230	258	254	261	332	397	413	363	467	658	745
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	362	365	392	395	353	372	379	364	445	497	1,045
Selling, General & Admin Expense	105	120	111	119	121	132	127	139	128	164	134
Research & Development Expense	217	214	246	242	194	196	200	180	224	200	773
Amortization Expense	0.18	0.18	0.18	0.18	0.44	0.76	0.60	0.60	0.60	0.60	0.60
Other Operating Expenses / (Income)	40	31	35	34	37	44	51	45	92	132	138
Total Other Income / (Expense), net	-125	-29	-375	119	-12	16	6.54	14	12	10	-83
Other Income / (Expense), net	0.00	-	13	119	-12	16	6.54	14	12	10	-83
Income Tax Expense	1.32	7.94	4.05	9.36	7.76	-5.28	5.33	7.12	0.40	13	64
Basic Earnings per Share	($2.94)	($1.24)	($5.86)	($0.27)	($0.46)	$0.79	$0.38	$0.07	$0.35	$1.67	($4.60)
Weighted Average Basic Shares Outstanding	87.63M	87.56M	88.19M	88.74M	88.89M	92.40M	93.99M	94.62M	95.39M	95.08M	97.36M
Diluted Earnings per Share	($2.94)	($1.24)	($5.86)	($0.27)	($0.46)	$0.79	$0.37	$0.07	$0.34	$1.56	($4.60)
Weighted Average Diluted Shares Outstanding	87.63M	87.56M	88.19M	88.74M	88.89M	92.40M	99.11M	99.14M	100.45M	107.88M	97.36M
Weighted Average Basic & Diluted Shares Outstanding	87.78M	87.98M	93.15M	93.28M	93.55M	93.86M	94.52M	95.37M	95.52M	97.03M	98.28M

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	6.75	42	477	-229	473	668	614	-1,140	-542	675
Net Cash From Operating Activities	-149	-246	-232	-389	-456	107	-443	-325	-501	-206
Net Cash From Continuing Operating Activities	-149	-246	-232	-389	-456	107	-443	-325	-501	-206
Net Income / (Loss) Continuing Operations	-220	-267	-51	-362	-715	-554	-419	-703	-536	235
Consolidated Net Income / (Loss)	-220	-267	-51	-362	-715	-554	-419	-703	-536	235
Depreciation Expense	5.25	5.61	8.09	12	25	27	38	42	44	38
Non-Cash Adjustments To Reconcile Net Income	33	32	-78	77	301	81	36	418	459	49
Changes in Operating Assets and Liabilities, net	32	-16	-110	-108	-67	554	-98	-82	-469	-528
Net Cash From Investing Activities	8.41	-90	-179	-370	287	-122	495	-1,047	-166	756
Net Cash From Continuing Investing Activities	8.41	-90	-179	-370	287	-122	495	-1,047	-166	756
Purchase of Property, Plant & Equipment	-3.40	-5.34	-12	-61	-60	-82	-38	-31	-76	-137
Acquisitions	-1.43	-1.53	-9.22	0.00	-173	-	-2.31	-1.43	-11	-10
Purchase of Investments	-173	-195	-590	-1,172	-1,194	-1,334	-32	-1,938	-2,049	-1,100
Divestitures	-	-	125	0.00	0.00	108	102	0.00	102	0.00
Sale and/or Maturity of Investments	186	112	307	866	1,716	1,189	466	923	1,868	2,002
Net Cash From Financing Activities	148	378	888	530	643	682	562	233	125	125
Net Cash From Continuing Financing Activities	148	378	888	530	643	682	562	233	125	125
Repayment of Debt	-3.00	-2.60	-55	-269	-0.69	0.00	0.00	-576	0.00	-0.07
Repurchase of Preferred Equity	-	-	-	-	-	0.00	0.00	-248	0.00	0.00
Issuance of Debt	20	-	640	236	246	291	0.00	1,127	-6.89	0.00
Other Financing Activities, net	11	-5.00	-51	50	32	79	13	-71	132	125
Cash Interest Paid	0.77	1.56	1.91	11	8.55	34	56	44	16	16
Cash Income Taxes Paid	-	-	5.34	1.55	0.93	2.51	0.58	1.70	15	23

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	171	-72	-95	-20	-310	-117	-1.14	-44	-186	905	-862
Net Cash From Operating Activities	-65	-92	-209	-122	-115	-55	-242	15	-71	92	-583
Net Cash From Continuing Operating Activities	-65	-92	-209	-122	-116	-53	-242	15	-71	92	-583
Net Income / (Loss) Continuing Operations	-258	-109	-517	-24	-41	46	36	6.46	34	159	-448
Consolidated Net Income / (Loss)	-258	-109	-517	-24	-41	46	36	6.46	34	159	-448
Depreciation Expense	11	11	11	11	11	11	8.74	8.72	9.81	10	9.98
Non-Cash Adjustments To Reconcile Net Income	172	100	418	-53	75	19	-102	-13	70	94	207
Changes in Operating Assets and Liabilities, net	9.99	-94	-122	-56	-161	-130	-185	13	-184	-172	-353
Net Cash From Investing Activities	19	9.80	12	97	-211	-64	219	-99	-129	764	-291
Net Cash From Continuing Investing Activities	19	9.80	12	97	-211	-64	219	-99	-129	764	-291
Purchase of Property, Plant & Equipment	-8.23	-7.96	-9.49	-18	-30	-19	-32	-29	-37	-38	-44
Acquisitions	-	-0.20	-0.09	-0.05	-11	-	-10	-	-	-	-2.24
Purchase of Investments	-372	-429	-427	-403	-646	-574	-216	-331	-389	-163	-286
Sale and/or Maturity of Investments	400	447	449	416	476	528	478	261	298	965	41
Net Cash From Financing Activities	216	11	102	5.86	15	1.94	22	40	14	49	12
Net Cash From Continuing Financing Activities	216	11	102	5.86	15	1.94	22	40	14	49	12
Other Financing Activities, net	-88	11	102	5.86	15	8.83	22	40	14	49	12
Cash Interest Paid	13	3.15	7.02	0.79	7.31	0.79	7.19	0.79	7.19	0.69	7.19
Cash Income Taxes Paid	-	0.34	0.54	5.46	3.58	5.51	0.91	7.08	3.62	11	0.84

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	274	424	1,308	1,642	1,823	2,985	3,148	3,128	3,265	3,963
Total Current Assets	225	373	1,229	1,426	1,469	2,485	2,604	2,558	2,579	3,073
Cash & Equivalents	80	122	600	371	835	1,503	2,116	967	428	1,103
Short-Term Investments	112	195	479	803	290	436	0.00	1,023	1,248	252
Accounts Receivable	3.98	5.23	29	49	91	101	153	215	400	602
Inventories, net	-	13	84	125	171	232	186	204	323	750
Prepaid Expenses	-	-	-	-	-	-	-	-	102	276
Other Current Assets	17	27	37	78	82	213	149	150	78	90
Plant, Property, & Equipment, net	37	38	43	97	130	190	191	180	227	340
Total Noncurrent Assets	12	13	36	119	224	309	353	390	458	549
Long-Term Investments	0.78	4.75	22	-	-	-	-	-	0.00	133
Other Noncurrent Operating Assets	4.47	-	-	107	212	295	338	390	458	416
Total Liabilities & Shareholders' Equity	274	424	1,308	1,642	1,823	2,985	3,148	3,128	3,265	3,963
Total Liabilities	83	87	519	610	1,005	2,223	2,220	2,743	2,405	2,435
Total Current Liabilities	62	75	88	174	265	416	453	620	654	732
Short-Term Debt	8.43	10	6.18	-	-	-	-	0.00	105	0.00
Accounts Payable	20	30	8.47	34	68	111	77	96	165	214
Accrued Expenses	29	31	69	134	186	194	272	419	315	374
Current Deferred Revenue	3.30	3.30	3.32	-	3.30	89	89	89	50	130
Other Current Liabilities	1.28	1.31	1.39	5.77	7.84	22	15	15	18	13
Total Noncurrent Liabilities	21	12	430	436	740	1,143	1,767	2,124	1,752	1,704
Long-Term Debt	15	6.04	425	421	682	992	1,097	1,544	1,133	1,137
Noncurrent Deferred Revenue	-	-	-	-	0.00	0.00	574	485	437	325
Other Noncurrent Operating Liabilities	6.17	5.95	5.54	16	58	151	96	95	182	242
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	190	337	789	1,032	818	762	928	385	859	1,528
Total Preferred & Common Equity	190	337	789	1,032	818	762	928	385	859	1,528
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	190	337	789	1,032	818	762	928	385	859	1,528
Common Stock	1,090	1,503	2,007	2,611	3,112	3,610	4,135	4,297	5,305	5,739
Retained Earnings	-899	-1,166	-1,217	-1,579	-2,294	-2,848	-3,207	-3,910	-4,446	-4,211
Accumulated Other Comprehensive Income / (Loss)	-0.11	-0.12	-0.38	-0.10	0.05	0.00	-0.02	-1.66	0.92	-0.22

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	3,156	3,060	3,126	3,110	3,224	3,424	3,600	3,465
Total Current Assets	2,626	2,488	2,473	2,451	2,465	2,684	2,685	2,433
Cash & Equivalents	1,039	872	852	542	427	384	198	241
Short-Term Investments	1,034	1,010	1,009	1,192	963	1,077	1,001	282
Accounts Receivable	202	224	237	319	379	360	435	659
Inventories, net	221	203	227	244	374	486	566	941
Prepaid Expenses	-	-	-	-	239	303	321	203
Other Current Assets	131	180	148	154	83	75	165	105
Plant, Property, & Equipment, net	181	183	189	212	249	276	306	361
Total Noncurrent Assets	349	389	464	446	510	464	609	672
Long-Term Investments	-	-	-	-	-	-	182	263
Other Noncurrent Operating Assets	336	389	464	446	510	464	427	409
Total Liabilities & Shareholders' Equity	3,156	3,060	3,126	3,110	3,224	3,424	3,600	3,465
Total Liabilities	2,725	2,347	2,384	2,345	2,263	2,347	2,379	2,323
Total Current Liabilities	603	537	499	451	609	688	699	606
Short-Term Debt	-	-	-	-	106	92	92	0.00
Accounts Payable	118	107	110	88	92	107	119	156
Accrued Expenses	369	346	327	322	283	350	345	392
Current Deferred Revenue	89	67	45	22	112	122	127	45
Other Current Liabilities	26	17	17	18	16	17	17	13
Total Noncurrent Liabilities	2,122	1,810	1,886	1,895	1,654	1,659	1,679	1,717
Long-Term Debt	1,543	1,234	1,236	1,237	1,134	1,135	1,136	1,138
Noncurrent Deferred Revenue	507	485	485	485	325	325	325	325
Other Noncurrent Operating Liabilities	72	91	165	173	196	199	218	254
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	431	713	741	764	961	1,077	1,221	1,143
Total Preferred & Common Equity	431	713	741	764	961	1,077	1,221	1,143
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	431	713	741	764	961	1,077	1,221	1,143
Common Stock	4,235	5,140	5,193	5,257	5,372	5,482	5,589	5,801
Retained Earnings	-3,801	-4,427	-4,451	-4,492	-4,410	-4,404	-4,370	-4,658
Accumulated Other Comprehensive Income / (Loss)	-3.21	-0.42	-1.06	-0.64	-0.69	-1.03	2.25	0.03

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-87.16%	332.64%	2,751.58%	94.74%	26.51%	41.82%	29.96%	32.93%	33.26%	52.97%
EBITDA Growth	-65.14%	-22.16%	84.16%	-764.32%	-92.54%	23.68%	27.60%	-37.21%	83.09%	437.77%
EBIT Growth	-62.04%	-21.47%	81.81%	-645.68%	-96.87%	22.53%	24.25%	-34.75%	76.48%	296.41%
NOPAT Growth	-64.58%	-21.14%	35.65%	-100.21%	-105.33%	20.04%	18.51%	-16.64%	50.05%	204.93%
Net Income Growth	-62.04%	-21.47%	81.03%	-614.01%	-97.58%	22.51%	24.43%	-67.99%	23.81%	143.89%
EPS Growth	-53.39%	-5.58%	84.34%	-534.88%	-77.84%	26.78%	27.57%	-55.92%	27.77%	140.34%
Operating Cash Flow Growth	-16.28%	-64.47%	5.62%	-67.53%	-17.45%	123.54%	-512.38%	26.59%	-53.99%	58.92%
Free Cash Flow Firm Growth	20.63%	-62.32%	-11.97%	-81.85%	-47.56%	15.51%	149.80%	-263.55%	-64.62%	16.39%
Invested Capital Growth	-77.19%	99.98%	510.74%	133.60%	34.57%	27.66%	-118.99%	33.91%	800.27%	179.49%
Revenue Q/Q Growth	4,540.74%	332.64%	50.48%	9.91%	4.30%	9.09%	8.72%	6.50%	12.52%	15.95%
EBITDA Q/Q Growth	-10.76%	-9.97%	60.30%	-48.43%	-13.09%	0.41%	23.10%	-5.86%	75.16%	77.63%
EBIT Q/Q Growth	-10.14%	-9.76%	56.29%	-46.94%	-15.04%	0.27%	21.03%	-5.48%	66.75%	101.52%
NOPAT Q/Q Growth	-9.84%	-9.86%	27.54%	-51.10%	-14.78%	9.54%	12.37%	-0.19%	32.92%	157.86%
Net Income Q/Q Growth	-10.14%	-9.76%	55.98%	-47.71%	-15.29%	7.72%	13.85%	1.78%	22.42%	93.06%
EPS Q/Q Growth	-7.66%	-3.78%	58.65%	-43.68%	-12.91%	9.54%	16.53%	2.31%	25.93%	49.04%
Operating Cash Flow Q/Q Growth	-4.05%	-25.51%	17.78%	-30.73%	-9.97%	-9.09%	24.68%	-24.05%	7.00%	41.62%
Free Cash Flow Firm Q/Q Growth	2.09%	-26.42%	13.81%	-28.39%	-7.21%	-393.80%	144.66%	-30.85%	-3.52%	22.84%
Invested Capital Q/Q Growth	-72.18%	-5.11%	8.52%	6.28%	-1.93%	314.31%	-162.41%	39.18%	57.37%	10.15%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-17,089.47%	-4,825.20%	-26.80%	-118.94%	-181.02%	-97.42%	-54.27%	-56.02%	-7.11%	15.69%
Operating Margin	-17,572.55%	-4,920.31%	-111.03%	-114.15%	-185.27%	-104.46%	-65.50%	-57.47%	-21.54%	11.47%
EBIT Margin	-17,560.26%	-4,930.18%	-31.46%	-120.45%	-187.45%	-102.40%	-59.69%	-60.51%	-10.68%	13.71%
Profit (Net Income) Margin	-17,560.26%	-4,930.18%	-32.79%	-120.23%	-187.77%	-102.60%	-59.66%	-75.40%	-43.11%	12.37%
Tax Burden Percent	100.00%	100.00%	104.24%	99.81%	100.17%	100.19%	99.96%	101.96%	103.05%	90.21%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	122.22%	391.73%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.79%
Return on Invested Capital (ROIC)	-585.70%	-1,273.35%	-172.94%	-120.78%	-150.98%	-92.43%	-165.80%	0.00%	-103.88%	24.62%
ROIC Less NNEP Spread (ROIC-NNEP)	-551.49%	-1,240.98%	-187.01%	-103.72%	-114.00%	-48.54%	-150.89%	0.00%	-24.97%	14.86%
Return on Net Nonoperating Assets (RNNOA)	485.23%	1,171.93%	163.93%	81.04%	73.69%	22.29%	116.23%	0.00%	17.73%	-4.91%
Return on Equity (ROE)	-100.47%	-101.42%	-9.00%	-39.74%	-77.29%	-70.15%	-49.57%	-107.16%	-86.15%	19.71%
Cash Return on Invested Capital (CROIC)	-459.99%	-1,340.01%	-316.66%	-200.87%	-180.45%	-116.73%	0.00%	0.00%	-158.80%	-69.98%
Operating Return on Assets (OROA)	-77.36%	-76.59%	-5.62%	-24.58%	-41.21%	-23.01%	-13.66%	-17.99%	-4.15%	7.22%
Return on Assets (ROA)	-77.36%	-76.59%	-5.85%	-24.54%	-41.28%	-23.05%	-13.66%	-22.42%	-16.77%	6.51%
Return on Common Equity (ROCE)	-100.47%	-101.42%	-9.00%	-39.74%	-77.29%	-70.15%	-49.57%	-107.16%	-86.15%	19.71%
Return on Equity Simple (ROE_SIMPLE)	-115.59%	-79.38%	-6.42%	-35.06%	-87.40%	-72.74%	-45.13%	-182.75%	-62.37%	15.40%
Net Operating Profit after Tax (NOPAT)	-154	-187	-120	-241	-494	-395	-322	-375	-187	197
NOPAT Margin	-12,300.78%	-3,444.22%	-77.72%	-79.90%	-129.69%	-73.12%	-45.85%	-40.23%	-15.08%	10.34%
Net Nonoperating Expense Percent (NNEP)	-34.20%	-32.37%	14.08%	-17.06%	-36.98%	-43.89%	-14.90%	-44.83%	-78.91%	9.76%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-19.46%	-8.94%	7.38%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	5,989.07%	1,544.90%	79.36%	69.02%	74.79%	58.86%	40.27%	48.38%	38.76%	29.33%
R&D to Revenue	11,683.48%	3,473.01%	107.84%	133.49%	192.77%	133.74%	109.87%	94.01%	70.57%	42.30%
Operating Expenses to Revenue	17,672.55%	5,020.31%	211.03%	214.15%	285.27%	204.46%	165.50%	157.47%	121.54%	88.53%
Earnings before Interest and Taxes (EBIT)	-220	-267	-49	-363	-714	-553	-419	-565	-133	261
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-214	-262	-41	-358	-689	-526	-381	-523	-88	298
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.18	4.45	4.56	7.06	11.76	17.66	8.45	29.55	10.50	7.60
Price to Tangible Book Value (P/TBV)	9.51	4.56	4.64	7.14	11.94	17.98	8.58	29.55	10.50	7.60
Price to Revenue (P/Rev)	1,393.91	276.22	23.26	24.22	25.26	24.91	11.17	12.19	7.26	6.11
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	49.37
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.03%
Enterprise Value to Invested Capital (EV/IC)	160.19	60.37	24.51	23.44	24.45	26.10	0.00	0.00	20.38	9.57
Enterprise Value to Revenue (EV/Rev)	1,249.80	217.72	18.93	21.72	24.10	23.16	9.72	11.71	6.90	5.92
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	37.73
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43.19
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	57.25
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	116.39	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	27.47	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.12	0.05	0.55	0.41	0.83	1.30	1.18	4.01	1.44	0.74
Long-Term Debt to Equity	0.08	0.02	0.54	0.41	0.83	1.30	1.18	4.01	1.32	0.74
Financial Leverage	-0.88	-0.94	-0.88	-0.78	-0.65	-0.46	-0.77	-1.12	-0.71	-0.33
Leverage Ratio	1.30	1.32	1.54	1.62	1.87	3.04	3.63	4.78	5.14	3.03
Compound Leverage Factor	1.30	1.32	1.54	1.62	1.87	3.04	3.63	5.84	20.13	3.03
Debt to Total Capital	10.95%	4.58%	35.32%	28.95%	45.46%	56.58%	54.17%	80.05%	59.03%	42.67%
Short-Term Debt to Total Capital	3.94%	2.86%	0.51%	0.00%	0.00%	0.00%	0.00%	0.00%	5.03%	0.00%
Long-Term Debt to Total Capital	7.00%	1.71%	34.82%	28.95%	45.46%	56.58%	54.17%	80.05%	54.00%	42.67%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	89.05%	95.42%	64.68%	71.05%	54.54%	43.42%	45.83%	19.95%	40.97%	57.33%
Debt to EBITDA	-0.11	-0.06	-10.41	-1.17	-0.99	-1.89	-2.88	-2.95	-14.01	3.81
Net Debt to EBITDA	0.84	1.21	16.17	2.10	0.64	1.80	2.68	0.85	4.96	-1.18
Long-Term Debt to EBITDA	-0.07	-0.02	-10.26	-1.17	-0.99	-1.89	-2.88	-2.95	-12.82	3.81
Debt to NOPAT	-0.15	-0.09	-3.59	-1.75	-1.38	-2.51	-3.41	-4.11	-6.60	5.78
Net Debt to NOPAT	1.17	1.70	5.58	3.13	0.90	2.40	3.17	1.19	2.34	-1.78
Long-Term Debt to NOPAT	-0.10	-0.03	-3.54	-1.75	-1.38	-2.51	-3.41	-4.11	-6.04	5.78
Altman Z-Score	6.03	5.20	3.90	6.20	3.69	2.70	1.30	1.18	1.30	2.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.60	4.95	13.91	8.21	5.55	5.97	5.75	4.13	3.95	4.20
Quick Ratio	3.15	4.28	12.55	7.04	4.59	4.90	5.01	3.56	3.18	2.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-121	-196	-220	-400	-590	-499	248	-406	-669	-559
Operating Cash Flow to CapEx	-4,394.74%	-4,602.51%	-1,933.30%	-635.51%	-765.48%	130.73%	-1,151.40%	-1,055.50%	-658.28%	-150.26%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.24	-1.73	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.59	-1.29	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.84	-1.49	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.02	0.18	0.20	0.22	0.22	0.23	0.30	0.39	0.53
Accounts Receivable Turnover	0.39	1.18	8.91	7.67	5.44	5.62	5.52	5.08	4.04	3.80
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.03	0.14	3.82	4.30	3.36	3.38	3.68	5.03	6.11	6.70
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	931.14	309.89	40.96	47.60	67.05	64.95	66.13	71.91	90.26	96.17
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	931.14	309.89	40.96	47.60	67.05	64.95	66.13	71.91	90.26	96.17
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	9.78	20	119	279	375	479	-91	-60	421	1,177
Invested Capital Turnover	0.05	0.37	2.23	1.51	1.16	1.26	3.62	-12.35	6.89	2.38
Increase / (Decrease) in Invested Capital	-33	9.77	100	160	96	104	-570	31	481	756
Enterprise Value (EV)	1,566	1,180	2,926	6,539	9,176	12,508	6,822	10,930	8,582	11,263
Market Capitalization	1,747	1,497	3,596	7,292	9,619	13,454	7,841	11,375	9,021	11,614
Book Value per Share	$4.20	$6.17	$12.21	$15.45	$10.98	$9.65	$10.66	$4.39	$9.19	$15.99
Tangible Book Value per Share	$4.06	$6.02	$11.99	$15.27	$10.81	$9.48	$10.49	$4.39	$9.19	$15.99
Total Capital	214	353	1,220	1,453	1,500	1,754	2,025	1,929	2,097	2,665
Total Debt	23	16	431	421	682	992	1,097	1,544	1,238	1,137
Total Long-Term Debt	15	6.04	425	421	682	992	1,097	1,544	1,133	1,137
Net Debt	-181	-317	-670	-753	-443	-946	-1,019	-445	-438	-351
Capital Expenditures (CapEx)	3.40	5.34	12	61	60	82	38	31	76	137
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-33	-20	67	79	79	131	35	-51	355	987
Debt-free Net Working Capital (DFNWC)	171	308	1,146	1,252	1,204	2,069	2,151	1,938	2,031	2,342
Net Working Capital (NWC)	162	298	1,140	1,252	1,204	2,069	2,151	1,938	1,926	2,342
Net Nonoperating Expense (NNE)	66	81	-69	121	221	159	97	328	349	-39
Net Nonoperating Obligations (NNO)	-181	-317	-670	-753	-443	-283	-1,019	-445	-438	-351
Total Depreciation and Amortization (D&A)	5.90	5.69	7.20	4.57	25	27	38	42	44	38
Debt-free, Cash-free Net Working Capital to Revenue	-2,594.41%	-375.91%	43.62%	26.10%	20.85%	24.18%	5.06%	-5.48%	28.54%	51.89%
Debt-free Net Working Capital to Revenue	13,621.55%	5,684.60%	741.66%	416.06%	316.19%	383.11%	306.51%	207.74%	163.36%	123.12%
Net Working Capital to Revenue	12,948.84%	5,498.14%	737.67%	416.06%	316.19%	383.11%	306.51%	207.74%	154.88%	123.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.20)	($5.49)	($0.86)	($5.46)	($9.71)	($7.11)	($5.15)	($8.03)	($5.80)	$2.47
Adjusted Weighted Average Basic Shares Outstanding	45.67M	54.81M	64.98M	71.29M	77.78M	79.42M	87.15M	87.56M	92.40M	95.08M
Adjusted Diluted Earnings per Share	($5.20)	($5.49)	($0.86)	($5.46)	($9.71)	($7.11)	($5.15)	($8.03)	($5.80)	$2.34
Adjusted Weighted Average Diluted Shares Outstanding	45.67M	54.81M	64.98M	71.29M	77.78M	79.42M	87.15M	87.56M	92.40M	107.88M
Adjusted Basic & Diluted Earnings per Share	($5.20)	($5.49)	($0.86)	($5.46)	($9.71)	($7.11)	($5.15)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	42.29M	48.70M	58.82M	66.25M	73.62M	77.96M	81.26M	87.98M	93.86M	97.03M
Normalized Net Operating Profit after Tax (NOPAT)	-154	-187	-120	-241	-494	-395	-322	-375	-187	197
Normalized NOPAT Margin	-12,300.78%	-3,444.22%	-77.72%	-79.90%	-129.69%	-73.12%	-45.85%	-40.23%	-15.08%	10.34%
Pre Tax Income Margin	-17,560.26%	-4,930.18%	-31.46%	-120.45%	-187.45%	-102.40%	-59.69%	-73.95%	-41.83%	13.71%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-4.50	-0.34	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.99	-0.48	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-4.75	-0.54	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.24	-0.68	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.57%	28.28%	20.24%	11.89%	44.10%	53.54%	63.10%	38.93%	40.79%	65.94%	80.15%
EBITDA Growth	-222.50%	13.84%	-49.78%	98.12%	81.56%	153.74%	144.00%	687.82%	296.94%	252.12%	-844.22%
EBIT Growth	-174.19%	12.35%	-44.31%	93.09%	74.74%	137.79%	133.06%	193.09%	202.51%	325.41%	-1,025.30%
NOPAT Growth	-281.20%	-0.96%	-58.94%	36.76%	84.13%	137.24%	131.47%	99.64%	250.37%	437.67%	-791.29%
Net Income Growth	-435.35%	10.44%	-392.03%	89.66%	84.12%	141.79%	106.99%	126.98%	182.10%	248.37%	-1,338.98%
EPS Growth	-390.00%	13.29%	-388.33%	89.81%	84.35%	163.71%	106.31%	125.93%	173.91%	97.47%	-1,343.24%
Operating Cash Flow Growth	47.75%	-215.05%	-106.96%	-82.94%	-76.57%	40.84%	-15.61%	112.22%	38.37%	268.41%	-141.01%
Free Cash Flow Firm Growth	86.98%	-121.29%	-91.68%	-58.12%	-1,273.22%	-329.18%	-225.75%	-134.25%	-104.43%	-33.69%	-25.34%
Invested Capital Growth	-185.16%	33.91%	212.56%	215.42%	370.62%	800.27%	1,146.91%	625.31%	299.32%	179.49%	84.61%
Revenue Q/Q Growth	-1.38%	12.23%	-1.91%	3.05%	27.02%	19.58%	4.20%	-12.22%	28.72%	40.94%	13.13%
EBITDA Q/Q Growth	40.05%	20.20%	-18.48%	96.68%	-486.50%	332.59%	27.36%	-55.58%	96.50%	315.86%	-305.02%
EBIT Q/Q Growth	37.79%	18.67%	-17.36%	88.37%	-127.45%	221.69%	47.82%	-67.24%	150.47%	405.04%	-323.31%
NOPAT Q/Q Growth	37.79%	18.67%	-29.26%	3.31%	84.39%	290.88%	9.23%	-101.10%	6,677.39%	582.51%	-240.43%
Net Income Q/Q Growth	-11.34%	57.61%	-373.03%	95.37%	-71.00%	211.53%	-20.89%	-82.11%	420.29%	373.21%	-381.36%
EPS Q/Q Growth	-10.94%	57.82%	-372.58%	95.39%	-70.37%	271.74%	-53.16%	-81.08%	385.71%	358.82%	-394.87%
Operating Cash Flow Q/Q Growth	2.77%	-42.22%	-126.64%	41.63%	6.16%	52.35%	-342.90%	106.17%	-573.16%	230.19%	-733.85%
Free Cash Flow Firm Q/Q Growth	85.86%	-280.70%	-107.59%	-41.53%	-22.77%	-18.98%	-57.56%	-1.78%	-7.14%	22.19%	-47.72%
Invested Capital Q/Q Growth	1.80%	39.18%	207.99%	78.97%	130.24%	57.37%	92.29%	4.10%	26.76%	10.15%	27.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-52.40%	-37.26%	-45.00%	-1.45%	-6.70%	13.04%	12.14%	6.14%	9.38%	27.67%	-50.15%
Operating Margin	-57.04%	-41.34%	-54.47%	-51.11%	-6.28%	6.21%	8.44%	-0.19%	4.75%	24.56%	-40.33%
EBIT Margin	-57.04%	-41.34%	-49.46%	-5.58%	-10.00%	10.17%	10.02%	3.74%	7.28%	26.08%	-51.49%
Profit (Net Income) Margin	-111.93%	-42.27%	-203.85%	-9.16%	-12.34%	11.51%	8.74%	1.78%	7.19%	24.16%	-60.08%
Tax Burden Percent	100.51%	107.84%	100.79%	164.14%	123.40%	113.09%	87.14%	47.58%	98.84%	92.61%	116.69%
Interest Burden Percent	195.21%	94.83%	408.92%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	-13.09%	12.86%	52.42%	1.16%	7.39%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-10,271.56%	-4,625.09%	-57.60%	48.35%	23.61%	-0.29%	11.53%	54.13%	-54.72%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-10,217.78%	-4,634.66%	-52.47%	44.32%	22.18%	-1.87%	7.94%	51.77%	-291.32%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	10,170.63%	4,585.65%	45.06%	-31.46%	-10.59%	0.88%	-2.60%	-17.11%	-27.77%
Return on Equity (ROE)	-159.10%	-107.16%	-100.93%	-39.44%	-12.54%	16.89%	13.02%	0.60%	8.94%	37.02%	-82.49%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-822.06%	-493.71%	-241.41%	-158.80%	-181.06%	-145.51%	-108.47%	-69.98%	-66.58%
Operating Return on Assets (OROA)	-17.18%	-12.29%	-15.78%	-1.83%	-3.53%	3.96%	4.48%	1.72%	3.56%	13.73%	-34.38%
Return on Assets (ROA)	-33.71%	-12.57%	-65.04%	-3.00%	-4.35%	4.48%	3.90%	0.82%	3.52%	12.71%	-40.12%
Return on Common Equity (ROCE)	-159.10%	-107.16%	-100.93%	-39.44%	-12.54%	16.89%	13.02%	0.60%	8.94%	37.02%	-82.49%
Return on Equity Simple (ROE_SIMPLE)	-166.24%	0.00%	-156.47%	-122.43%	-90.39%	0.00%	1.76%	4.39%	9.98%	0.00%	-21.74%
Net Operating Profit after Tax (NOPAT)	-92	-75	-97	-93	-15	28	30	-0.33	22	150	-210
NOPAT Margin	-39.93%	-28.94%	-38.13%	-35.78%	-4.40%	7.02%	7.36%	-0.09%	4.70%	22.74%	-28.23%
Net Nonoperating Expense Percent (NNEP)	-32.07%	-4.71%	-53.78%	9.57%	-5.13%	4.03%	1.43%	1.58%	3.60%	2.36%	236.60%
Return On Investment Capital (ROIC_SIMPLE)	-	-3.88%	-	-	-	1.33%	-	-	-	5.62%	-9.22%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	45.51%	46.62%	43.67%	45.39%	36.43%	33.19%	30.72%	38.24%	27.44%	24.89%	17.94%
R&D to Revenue	94.11%	82.73%	96.91%	92.59%	58.56%	49.28%	48.47%	49.51%	48.05%	30.37%	103.84%
Operating Expenses to Revenue	157.04%	141.34%	154.47%	151.11%	106.28%	93.79%	91.56%	100.19%	95.25%	75.44%	140.33%
Earnings before Interest and Taxes (EBIT)	-131	-107	-125	-15	-33	40	41	14	34	172	-384
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-121	-96	-114	-3.79	-22	52	50	22	44	182	-374
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	22.47	29.55	17.01	14.39	14.79	10.50	12.60	13.87	9.75	7.60	5.42
Price to Tangible Book Value (P/TBV)	23.17	29.55	17.01	14.39	14.79	10.50	12.60	13.87	9.75	7.60	5.42
Price to Revenue (P/Rev)	11.05	12.19	12.43	10.63	10.23	7.26	8.63	9.92	7.26	6.11	2.77
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	716.73	313.79	95.28	49.37	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.14%	0.32%	1.05%	2.03%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	176.77	86.41	40.40	20.38	14.77	17.44	11.00	9.57	4.38
Enterprise Value to Revenue (EV/Rev)	10.44	11.71	11.76	10.01	9.78	6.90	8.52	9.77	7.17	5.92	2.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	157.57	144.14	69.97	37.73	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	351.12	236.26	90.86	43.19	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	509.11	154.11	57.25	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.58	4.01	1.73	1.67	1.62	1.44	1.29	1.14	1.01	0.74	1.00
Long-Term Debt to Equity	3.58	4.01	1.73	1.67	1.62	1.32	1.18	1.05	0.93	0.74	1.00
Financial Leverage	-1.15	-1.12	-1.00	-0.99	-0.86	-0.71	-0.48	-0.47	-0.33	-0.33	0.10
Leverage Ratio	6.46	4.78	3.90	4.17	5.24	5.14	3.75	3.60	3.38	3.03	3.18
Compound Leverage Factor	12.61	4.53	15.93	4.17	5.24	5.14	3.75	3.60	3.38	3.03	3.18
Debt to Total Capital	78.17%	80.05%	63.39%	62.50%	61.80%	59.03%	56.32%	53.24%	50.13%	42.67%	49.90%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	5.03%	4.80%	3.97%	3.74%	0.00%	0.00%
Long-Term Debt to Total Capital	78.17%	80.05%	63.39%	62.50%	61.80%	54.00%	51.52%	49.27%	46.39%	42.67%	49.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	21.83%	19.95%	36.61%	37.50%	38.20%	40.97%	43.68%	46.76%	49.87%	57.33%	50.10%
Debt to EBITDA	-3.12	-2.95	-2.26	-2.65	-3.48	-14.01	16.33	12.02	7.31	3.81	-9.09
Net Debt to EBITDA	1.07	0.85	1.19	1.34	1.40	4.96	-2.00	-2.30	-0.91	-1.18	-2.81
Long-Term Debt to EBITDA	-3.12	-2.95	-2.26	-2.65	-3.48	-12.82	14.94	11.13	6.76	3.81	-9.09
Debt to NOPAT	-4.12	-4.11	-3.00	-3.46	-4.42	-6.60	-26.34	42.47	16.09	5.78	-13.87
Net Debt to NOPAT	1.41	1.19	1.58	1.75	1.78	2.34	3.22	-8.11	-2.00	-1.78	-4.29
Long-Term Debt to NOPAT	-4.12	-4.11	-3.00	-3.46	-4.42	-6.04	-24.10	39.30	14.89	5.78	-13.87
Altman Z-Score	1.35	1.67	2.02	1.75	1.96	1.47	2.46	3.17	2.45	2.71	0.63
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.36	4.13	4.63	4.96	5.44	3.95	4.05	3.90	3.84	4.20	4.02
Quick Ratio	3.77	3.56	3.92	4.21	4.55	3.18	2.91	2.64	2.33	2.67	1.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-28	-106	-219	-310	-381	-453	-714	-727	-779	-606	-895
Operating Cash Flow to CapEx	-789.26%	-1,160.12%	-2,207.65%	-682.53%	-386.57%	-287.08%	-746.13%	51.23%	-189.73%	241.70%	-1,336.59%
Free Cash Flow to Firm to Interest Expense	-0.22	0.00	-0.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-0.52	0.00	-0.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-0.58	0.00	-0.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.30	0.32	0.33	0.35	0.39	0.45	0.46	0.49	0.53	0.67
Accounts Receivable Turnover	4.99	5.08	4.85	4.55	4.25	4.04	4.66	5.04	4.35	3.80	4.30
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.61	5.03	5.27	5.39	5.62	6.11	6.49	6.47	6.33	6.70	7.32
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	73.18	71.91	75.20	80.15	85.94	90.26	78.37	72.37	83.82	96.17	84.83
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	73.18	71.91	75.20	80.15	85.94	90.26	78.37	72.37	83.82	96.17	84.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-99	-60	65	116	268	421	810	843	1,068	1,177	1,495
Invested Capital Turnover	-13.12	-12.35	269.38	129.28	13.10	6.89	3.21	3.14	2.46	2.38	1.94
Increase / (Decrease) in Invested Capital	-64	31	123	217	366	481	745	727	801	756	685
Enterprise Value (EV)	9,150	10,930	11,479	10,042	10,810	8,582	11,959	14,701	11,758	11,263	6,545
Market Capitalization	9,680	11,375	12,127	10,667	11,307	9,021	12,111	14,935	11,910	11,614	6,193
Book Value per Share	$4.92	$4.39	$8.10	$7.96	$8.19	$9.19	$10.23	$11.39	$12.80	$15.99	$11.78
Tangible Book Value per Share	$4.77	$4.39	$8.10	$7.96	$8.19	$9.19	$10.23	$11.39	$12.80	$15.99	$11.78
Total Capital	1,974	1,929	1,947	1,977	2,001	2,097	2,200	2,303	2,449	2,665	2,281
Total Debt	1,543	1,544	1,234	1,236	1,237	1,238	1,239	1,226	1,228	1,137	1,138
Total Long-Term Debt	1,543	1,544	1,234	1,236	1,237	1,133	1,134	1,135	1,136	1,137	1,138
Net Debt	-530	-445	-648	-625	-497	-438	-151	-234	-153	-351	352
Capital Expenditures (CapEx)	8.23	7.96	9.49	18	30	19	32	29	37	38	44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-49	-51	69	113	267	355	571	626	879	987	1,304
Debt-free Net Working Capital (DFNWC)	2,023	1,938	1,951	1,974	2,000	2,031	1,962	2,087	2,077	2,342	1,827
Net Working Capital (NWC)	2,023	1,938	1,951	1,974	2,000	1,926	1,856	1,995	1,986	2,342	1,827
Net Nonoperating Expense (NNE)	166	34	420	-70	26	-18	-5.70	-6.79	-12	-9.32	237
Net Nonoperating Obligations (NNO)	-530	-445	-648	-625	-497	-438	-151	-234	-153	-351	352
Total Depreciation and Amortization (D&A)	11	11	11	11	11	11	8.74	8.72	9.81	10	9.98
Debt-free, Cash-free Net Working Capital to Revenue	-5.65%	-5.48%	7.11%	11.29%	24.12%	28.54%	40.69%	41.61%	53.59%	51.89%	58.40%
Debt-free Net Working Capital to Revenue	230.93%	207.74%	200.01%	196.72%	181.01%	163.36%	139.79%	138.65%	126.65%	123.12%	81.80%
Net Working Capital to Revenue	230.93%	207.74%	200.01%	196.72%	181.01%	154.88%	132.27%	132.57%	121.06%	123.12%	81.80%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.94)	($1.24)	($5.86)	($0.27)	($0.46)	$0.79	$0.38	$0.07	$0.35	$1.67	($4.60)
Adjusted Weighted Average Basic Shares Outstanding	87.63M	87.56M	88.19M	88.74M	88.89M	92.40M	93.99M	94.62M	95.39M	95.08M	97.36M
Adjusted Diluted Earnings per Share	($2.94)	($1.24)	($5.86)	($0.27)	($0.46)	$0.79	$0.37	$0.07	$0.34	$1.56	($4.60)
Adjusted Weighted Average Diluted Shares Outstanding	87.63M	87.56M	88.19M	88.74M	88.89M	92.40M	99.11M	99.14M	100.45M	107.88M	97.36M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	87.78M	87.98M	93.15M	93.28M	93.55M	93.86M	94.52M	95.37M	95.52M	97.03M	98.28M
Normalized Net Operating Profit after Tax (NOPAT)	-92	-75	-97	-93	-15	17	30	-0.49	22	150	-210
Normalized NOPAT Margin	-39.93%	-28.94%	-38.13%	-35.78%	-4.40%	4.34%	7.36%	-0.14%	4.70%	22.74%	-28.23%
Pre Tax Income Margin	-111.36%	-39.20%	-202.25%	-5.58%	-10.00%	10.17%	10.02%	3.74%	7.28%	26.08%	-51.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.05	0.00	-0.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-0.73	0.00	-0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-1.11	0.00	-0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-0.80	0.00	-0.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Sarepta Therapeutics (NASDAQ: SRPT) has shown significant fluctuations in its financial performance over the last four years, with recent quarterly results reflecting some challenges.

Recent Quarterly Performance (Q1 2025 vs. Previous Quarters):

Operating revenue increased to $745 million in Q1 2025 from $658 million in Q4 2024, indicating healthy top-line growth.
Total gross profit remains strong at $745 million, maintaining a 100% gross margin as cost of revenue was reported at zero, consistent with prior periods.
Total operating expenses surged dramatically to about $1.045 billion in Q1 2025, primarily driven by a spike in research & development expense ($773 million, up from $200 million in Q4 2024) and increased other operating expenses ($138 million vs. $132 million), leading to a large operating loss of $300 million compared to operating income of $162 million in Q4 2024.
Net income in Q1 2025 was a loss of approximately $448 million, a sharp decline from a positive net income of $159 million in the prior quarter, reflecting increased spending and other expenses.
Cash flow from operating activities turned negative at -$583 million in Q1 2025, a significant deterioration from positive operating cash flow of $92 million in Q4 2024, signaling higher consumption of cash in core operations.
Investing activities showed a cash outflow of about $291 million in Q1 2025 due to investments in property and marketable securities, consistent with ongoing capital expenditures and acquisitions.
Financing activities provided a small cash inflow of $12 million in Q1 2025, less than prior quarters, indicating limited financing activity.
Cash and equivalents stood at $241 million at quarter-end Q1 2025, down from $427 million at Q1 2024 and $198 million at Q3 2024, reflecting cash usage trends.
Total liabilities decreased slightly to $2.32 billion in Q1 2025 from $2.37 billion in Q3 2024, while total equity declined to about $1.14 billion from $1.22 billion in Q3 2024, showing some erosion in shareholder value.
Diluted shares outstanding have remained relatively stable, around 97 million in Q1 2025, showing no significant dilution despite losses.

Trend Analysis Over Past Four Years:

Revenue has grown consistently from around $230 million in Q3 2022 to $745 million in Q1 2025, driven by Sarepta’s expanding product portfolio and market penetration.
Earnings per share have been volatile, swinging from losses in 2022 and early 2023 (e.g., -$2.94 per share in Q3 2022 and -$5.86 in Q1 2023) to positive territory in late 2023 and 2024 (up to $1.67 in Q4 2024), then back to large losses in Q1 2025 (-$4.60), primarily due to fluctuating R&D and operating expenses.
Operating expenses have generally increased, especially R&D, which surged heavily in Q1 2025 likely reflecting investment in new drug development or clinical trials.
Cash flow from operating activities has been mixed, with some quarters positive and others significantly negative, correlating with profitability swings.
Inventory levels and accounts receivable have steadily increased in line with business growth, indicating higher operational scale and working capital needs.
Long-term debt has remained relatively stable around $1.1 to $1.5 billion over the years, suggesting ongoing leverage but no dramatic shifts.
The company maintains a sizable investment position in short-term and long-term securities, supporting liquidity.
Despite fluctuation in earnings, common equity has grown from roughly $430 million at end 2022 to over $1.1 billion in Q1 2025, reflecting capital raises and retained earnings fluctuations.
Significant net losses in the first quarters of 2023 and 2025 highlight challenges in controlling costs relative to revenue during these periods.
Revenue growth and investment in R&D could bode well long term if new clinical successes materialize, fundamentally supporting future growth potential.

Summary: Sarepta Therapeutics has demonstrated strong revenue growth over the last several years but faces recent profitability pressures mainly due to escalating R&D and other operating expenses. The large net loss and negative operating cash flow in Q1 2025 represent a setback following profitable quarters in late 2024. The company’s solid asset base and investment in strategic initiatives may position it for future growth, though managing expenses and returning to profitability remain key near-term challenges for investors to monitor.

10/07/25 02:02 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Sarepta Therapeutics' Financials

When does Sarepta Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Sarepta Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sarepta Therapeutics' net income changed over the last 9 years?

Over the last 9 years, Sarepta Therapeutics' net income changed from -$220.03 million in 2015 to $235.24 million in 2024, a change of -206.9%. Find out what analysts predict for Sarepta Therapeutics in the coming months.

What is Sarepta Therapeutics' operating income?

Sarepta Therapeutics' total operating income in 2024 was $218.08 million, based on the following breakdown:

Total Gross Profit: $1.90 billion
Total Operating Expenses: $1.68 billion

How has Sarepta Therapeutics' revenue changed over the last 9 years?

Over the last 9 years, Sarepta Therapeutics' total revenue changed from $1.25 million in 2015 to $1.90 billion in 2024, a change of 151,694.0%.

How much debt does Sarepta Therapeutics have?

Sarepta Therapeutics' total liabilities were at $2.44 billion at the end of 2024, a 1.3% increase from 2023, and a 2,819.0% increase since 2015.

How much cash does Sarepta Therapeutics have?

In the past 9 years, Sarepta Therapeutics' cash and equivalents has ranged from $80.30 million in 2015 to $2.12 billion in 2021, and is currently $1.10 billion as of their latest financial filing in 2024.

How has Sarepta Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Sarepta Therapeutics' book value per share changed from 4.20 in 2015 to 15.99 in 2024, a change of 280.4%.

Related Companies

This page (NASDAQ:SRPT) was last updated on 10/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Sarepta Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Financials

Annual Income Statements for Sarepta Therapeutics

Quarterly Income Statements for Sarepta Therapeutics

Annual Cash Flow Statements for Sarepta Therapeutics

Quarterly Cash Flow Statements for Sarepta Therapeutics

Annual Balance Sheets for Sarepta Therapeutics

Quarterly Balance Sheets for Sarepta Therapeutics

Annual Metrics And Ratios for Sarepta Therapeutics

Quarterly Metrics And Ratios for Sarepta Therapeutics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Sarepta Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools